Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease

Katz-Kiriakos, Ella; Steinberg, Deborah F.; Kluender, Colin E.; Osorio, Omar A.; Newsom-Stewart, Catie; Baronia, Arjun; Byers, Derek E.; Holtzman, Michael J.; Katafiasz, Dawn M.; Bailey, Kristina L.; Brody, Steven L.; Miller, Mark J.; Alexander‐Brett, Jennifer

doi:10.1172/jci.insight.136166

Cited by 19 publications

(24 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cumulant size (intensity-weighted Z-average) was reproducible between runs, and polydispersity was low, which indicated a relatively homogeneous distribution of particles. These results are consistent with measurements from cell line–derived EVs purified by size-exclusion chromatography and validated by transmission electron microscopy ( 18 ).…”

Section: Methodssupporting

confidence: 88%

Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin

Barlin

Erdmann-Gilmore

Mudd

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Section: Methodssupporting

confidence: 88%

Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin

Barlin

Erdmann-Gilmore

Mudd

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

“…Early studies showed that B cell-derived EVs can present allergen peptides and induce a T H 2 cell response 89 . Recent data have shown that IL-33, a cytokine known to induce T H 2 cell differentiation, is released by airway epithelial cells on the surface of exosomes 90 . In individuals with asthma, airway epithelial cell-derived EVs and EV-associated contactin 1 were identified as inducers of DC recruitment and activators of monocyte-derived DCs 91 .…”

Section: Allergic Responsesmentioning

confidence: 99%

The roles of extracellular vesicles in the immune system

2022

View full text Add to dashboard Cite

The twenty-first century has witnessed major developments in the field of extracellular vesicle (EV) research, including significant steps towards defining standard criteria for the separation and detection of EVs. The recent recognition that EVs have the potential to function as biomarkers or as therapeutic tools has attracted even greater attention to their study. With this progress in mind, an updated comprehensive overview of the roles of EVs in the immune system is timely. This Review summarizes the roles of EVs in basic processes of innate and adaptive immunity, including inflammation, antigen presentation, and the development and activation of B cells and T cells. It also highlights key progress related to deciphering the roles of EVs in antimicrobial defence and in allergic, autoimmune and antitumour immune responses. It ends with a focus on the relevance of EVs to immunotherapy and vaccination, drawing attention to ongoing or recently completed clinical trials that aim to harness the therapeutic potential of EVs.

show abstract

“…This is an important layer of regulation for homeostasis during cell turnover because apoptosis is a form of noninflammatory cell death. Constitutive signalling without additional protease processing has also been described, particularly with relation to changes in airway diseases [ 35 , 36 ]; a spliced variant of IL-33 has been linked to increased T2 cytokine activity in airway epithelial cells from asthmatics [ 35 ], whereas another isoform, IL-33 Δ34 , is increased in airway cells from COPD patients [ 36 ].…”

Section: Il-33 Pathwaymentioning

confidence: 99%

Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD

Calderón¹,

Dimond²,

Choy³

et al. 2023

Eur Respir Rev

View full text Add to dashboard Cite

Interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) are alarmins that are released upon airway epithelial injury from insults such as viruses and cigarette smoke, and play critical roles in the activation of immune cell populations such as mast cells, eosinophils and group 2 innate lymphoid cells. Both cytokines were previously understood to primarily drive type 2 (T2) inflammation, but there is emerging evidence for a role for these alarmins to additionally mediate non-T2 inflammation, with recent clinical trial data in asthma and COPD cohorts with non-T2 inflammation providing support. Currently available treatments for both COPD and asthma provide symptomatic relief with disease control, improving lung function and reducing exacerbation rates; however, there still remains an unmet need for further improving lung function and reducing exacerbations, particularly for those not responsive to currently available treatments. The epithelial cytokines/alarmins are involved in exacerbations; biologics targeting TSLP and IL-33 have been shown to reduce exacerbations in moderate-to-severe asthma, either in a broad population or in specific subgroups, respectively. For COPD, while there is clinical evidence for IL-33 blockade impacting exacerbations in COPD, clinical data from anti-TSLP therapies is awaited. Clinical data to date support an acceptable safety profile for patients with airway diseases for both anti-IL-33 and anti-TSLP antibodies in development. We examine the roles of IL-33 and TSLP, their potential use as drug targets, and the evidence for target patient populations for COPD and asthma, together with ongoing and future trials focused on these targets.

show abstract

Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease

Cited by 19 publications

References 66 publications

Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin

Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin

The roles of extracellular vesicles in the immune system

Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD

Contact Info

Product

Resources

About